NASDAQ:ALDR - Alder BioPharmaceuticals Stock Price, Price Target & More

$13.80 +0.15 (+1.10 %)
(As of 04/24/2018 10:30 AM ET)
Previous Close$13.65
Today's Range$13.60 - $13.88
52-Week Range$8.60 - $22.50
Volume97,247 shs
Average Volume1.63 million shs
Market Capitalization$932.87 million
P/E Ratio-2.76
Dividend YieldN/A
Beta2.53

About Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals logoAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDR
CUSIPN/A
Phone425-205-2900

Debt

Debt-to-Equity RatioN/A
Current Ratio12.30%
Quick Ratio12.30%

Price-To-Earnings

Trailing P/E Ratio-2.76
Forward P/E Ratio-3.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.62 million
Price / Sales577.98
Cash FlowN/A
Price / CashN/A
Book Value$4.12 per share
Price / Book3.35

Profitability

EPS (Most Recent Fiscal Year)($4.95)
Net Income$-288,870,000.00
Net MarginsN/A
Return on Equity-103.76%
Return on Assets-93.09%

Miscellaneous

Employees193
Outstanding Shares67,850,000

How to Become a New Pot Stock Millionaire

Alder BioPharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

What is Alder BioPharmaceuticals' stock symbol?

Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder BioPharmaceuticals' earnings last quarter?

Alder BioPharmaceuticals (NASDAQ:ALDR) announced its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.23. The biopharmaceutical company had revenue of $0.94 million for the quarter. During the same quarter in the previous year, the company posted ($0.97) EPS. View Alder BioPharmaceuticals' Earnings History.

What price target have analysts set for ALDR?

13 equities research analysts have issued twelve-month price objectives for Alder BioPharmaceuticals' shares. Their predictions range from $11.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $27.3077 in the next year. View Analyst Ratings for Alder BioPharmaceuticals.

What are Wall Street analysts saying about Alder BioPharmaceuticals stock?

Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
  • 1. Mizuho analysts commented, "We spoke with the company a couple of times late last week and this week after the announcement that CEO Randall Schatzman was stepping down. Our view on eptinezumab having a competitive and differentiated profile in the crowded migraine space has not changed. While the CEO transition brings uncertainties, it may help position the company as a commercial organization sooner. In our view, the best way to unlock the value of eptinezumab is through an acquisition by a larger company with substantial U.S. commercial experience. We recommend buying the shares on weakness." (3/28/2018)
  • 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (3/1/2018)
  • 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)

Are investors shorting Alder BioPharmaceuticals?

Alder BioPharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 10,860,160 shares, an increase of 17.7% from the March 15th total of 9,228,150 shares. Based on an average trading volume of 2,002,978 shares, the short-interest ratio is currently 5.4 days. Currently, 18.6% of the company's shares are sold short.

Who are some of Alder BioPharmaceuticals' key competitors?

Who are Alder BioPharmaceuticals' key executives?

Alder BioPharmaceuticals' management team includes the folowing people:
  • Dr. Randall C. Schatzman Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 63)
  • Dr. John A. Latham, Co-Founder, Chief Scientific Officer & Head of R&D (Age 58)
  • Mr. Larry K. Benedict, Principal Accounting Officer and Exec. VP (Age 57)
  • Ms. Elisabeth A. Sandoval, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 56)
  • Dr. Timothy M. Whitaker, Consultant (Age 59)

Has Alder BioPharmaceuticals been receiving favorable news coverage?

News stories about ALDR stock have trended somewhat positive on Tuesday, according to Accern. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alder BioPharmaceuticals earned a news impact score of 0.24 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Alder BioPharmaceuticals' major shareholders?

Alder BioPharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include REDMILE GROUP, LLC (9.99%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.

How do I buy shares of Alder BioPharmaceuticals?

Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder BioPharmaceuticals' stock price today?

One share of ALDR stock can currently be purchased for approximately $13.80.

How big of a company is Alder BioPharmaceuticals?

Alder BioPharmaceuticals has a market capitalization of $932.87 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Alder BioPharmaceuticals employs 193 workers across the globe.

How can I contact Alder BioPharmaceuticals?

Alder BioPharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]


MarketBeat Community Rating for Alder BioPharmaceuticals (ALDR)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alder BioPharmaceuticals (NASDAQ:ALDR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Alder BioPharmaceuticals in the last 12 months. Their average twelve-month price target is $27.3077, suggesting that the stock has a possible upside of 97.88%. The high price target for ALDR is $51.00 and the low price target for ALDR is $11.00. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.772.772.77
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.3077$29.3077$29.0769$29.2308
Price Target Upside: 97.88% upside96.70% upside62.44% upside182.42% upside

Alder BioPharmaceuticals (NASDAQ:ALDR) Consensus Price Target History

Price Target History for Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals (NASDAQ:ALDR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018Goldman SachsInitiated CoverageNeutral$17.00LowView Rating Details
3/28/2018MizuhoReiterated RatingBuy$29.00MediumView Rating Details
3/4/2018Leerink SwannReiterated RatingOutperformLowView Rating Details
2/26/2018CowenSet Price TargetBuy$23.00MediumView Rating Details
1/12/2018Canaccord GenuitySet Price TargetBuy -> Buy$20.00 -> $22.00LowView Rating Details
1/9/2018BMO Capital MarketsBoost Price TargetOutperform$26.00HighView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$17.00HighView Rating Details
8/24/2017Credit Suisse GroupSet Price TargetHold$17.00 -> $11.00HighView Rating Details
8/10/2017Needham & Company LLCReiterated RatingBuy$36.00 -> $26.00HighView Rating Details
7/5/2017AegisReiterated RatingBuy$41.00LowView Rating Details
6/28/2017Wells FargoReiterated RatingOutperform$51.00HighView Rating Details
6/28/2017Piper JaffrayReiterated RatingOverweight$47.00HighView Rating Details
5/5/2017UBSInitiated CoverageSell$13.00N/AView Rating Details
4/17/2017Jefferies GroupReiterated RatingBuy$43.00LowView Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00N/AView Rating Details
9/13/2016JPMorgan ChaseInitiated CoverageOverweight$40.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Alder BioPharmaceuticals (NASDAQ:ALDR) Earnings History and Estimates Chart

Earnings by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals (NASDAQ:ALDR) Earnings Estimates

2018 EPS Consensus Estimate: ($4.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.36)($1.36)($1.36)
Q2 20181($1.03)($1.03)($1.03)
Q3 20181($1.02)($1.02)($1.02)
Q4 20181($0.87)($0.87)($0.87)

Alder BioPharmaceuticals (NASDAQ ALDR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018Q4 2017($1.03)($0.80)$0.94 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.21)($0.92)ViewN/AView Earnings Details
8/8/2017Q2 2017($1.67)($1.48)$0.68 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.9520)($1.99)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.90)($0.97)ViewN/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.40)ViewListenView Earnings Details
3/4/2015Q414($0.18)($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.22)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/20/2014Q1($0.22)($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alder BioPharmaceuticals (NASDAQ:ALDR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 99.10%
Insider Trading History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Mark James LittonInsiderSell16,519$10.80$178,405.20116,451View SEC Filing  
10/16/2017Mark James LittonInsiderSell16,520$12.33$203,691.60116,452View SEC Filing  
7/18/2017Stephen M DowDirectorBuy25,000$10.00$250,000.00View SEC Filing  
6/20/2017Jeffrey T L SmithVPSell585$20.00$11,700.001,416View SEC Filing  
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80101,430View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00124,768View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.0099,567View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.003,000View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00252,200View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15122,949View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.003,000View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00124,768View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.003,000View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00252,200View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00243,013View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00124,768View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.0074,567View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.0016,090View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00252,200View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.0079,847View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05248,601View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00115,933View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00124,409View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.0073,718View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00111,579View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00241,726View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00111,579View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05241,265View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00109,921View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70241,265View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40209,447View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alder BioPharmaceuticals (NASDAQ ALDR) News Headlines

Source:
DateHeadline
Goldman Sachs Begins Coverage on Alder BioPharmaceuticals (ALDR)Goldman Sachs Begins Coverage on Alder BioPharmaceuticals (ALDR)
www.americanbankingnews.com - April 24 at 8:58 AM
Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical OfficerAlder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer
finance.yahoo.com - April 23 at 5:13 PM
Alder BioPharmaceuticals poaches Amgen vet for new chief operating officer roleAlder BioPharmaceuticals poaches Amgen vet for new chief operating officer role
finance.yahoo.com - April 23 at 5:13 PM
Alder BioPharmaceuticals (ALDR) Raised to Sell at ValuEngineAlder BioPharmaceuticals (ALDR) Raised to Sell at ValuEngine
www.americanbankingnews.com - April 20 at 7:28 PM
BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For EptinezumabBRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab
www.reuters.com - April 20 at 8:25 AM
Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for ...Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for ...
globenewswire.com - April 18 at 5:44 PM
Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology MeetingAlder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting
finance.yahoo.com - April 18 at 5:44 PM
Needham & Company LLC Analysts Give Alder BioPharmaceuticals (ALDR) a $36.00 Price TargetNeedham & Company LLC Analysts Give Alder BioPharmaceuticals (ALDR) a $36.00 Price Target
www.americanbankingnews.com - April 17 at 10:21 PM
Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating OfficerAlder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer
finance.yahoo.com - April 16 at 5:24 PM
Alder BioPharmaceuticals (ALDR) Expected to Post Earnings of -$1.26 Per ShareAlder BioPharmaceuticals (ALDR) Expected to Post Earnings of -$1.26 Per Share
www.americanbankingnews.com - April 16 at 1:25 AM
Alder BioPharmaceuticals (ALDR) Receives Consensus Rating of "Buy" from BrokeragesAlder BioPharmaceuticals (ALDR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 15 at 3:35 PM
Alder BioPharmaceuticals (ALDR) Raised to Buy at BidaskClubAlder BioPharmaceuticals (ALDR) Raised to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM
Alder BioPharmaceuticals (ALDR) Sees Large Increase in Short InterestAlder BioPharmaceuticals (ALDR) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 13 at 2:10 AM
Alder BioPharmaceuticals (ALDR) Cut to "Hold" at Zacks Investment ResearchAlder BioPharmaceuticals (ALDR) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 12 at 5:09 PM
Alder BioPharmaceuticals (ALDR) "Outperform" Rating Reaffirmed at BMO Capital MarketsAlder BioPharmaceuticals' (ALDR) "Outperform" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - April 11 at 6:45 PM
Alder BioPharmaceuticals (ALDR) Buy Rating Reiterated at Needham & Company LLCAlder BioPharmaceuticals' (ALDR) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - April 11 at 3:58 PM
Alder BioPharmaceuticals (ALDR) Now Covered by Analysts at CowenAlder BioPharmaceuticals (ALDR) Now Covered by Analysts at Cowen
www.americanbankingnews.com - April 8 at 5:25 PM
Alder BioPharmaceuticals (ALDR) Stock Rating Lowered by ValuEngineAlder BioPharmaceuticals (ALDR) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 6 at 1:55 PM
Medeor Therapeutics Expands Executive TeamMedeor Therapeutics Expands Executive Team
www.prnewswire.com - April 5 at 5:16 PM
Canaccord Genuity Initiates Coverage on Alder Biopharmaceuticals (ALDR)Canaccord Genuity Initiates Coverage on Alder Biopharmaceuticals (ALDR)
www.americanbankingnews.com - April 4 at 6:23 PM
BidaskClub Upgrades Alder Biopharmaceuticals (ALDR) to "Hold"BidaskClub Upgrades Alder Biopharmaceuticals (ALDR) to "Hold"
www.americanbankingnews.com - April 3 at 8:56 AM
Alder Biopharmaceuticals (ALDR) Rating Reiterated by BMO Capital MarketsAlder Biopharmaceuticals (ALDR) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - March 31 at 6:53 AM
Alder Biopharmaceuticals (ALDR) Rating Increased to Hold at BidaskClubAlder Biopharmaceuticals (ALDR) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
Mizuho Reiterates "Buy" Rating for Alder Biopharmaceuticals (ALDR)Mizuho Reiterates "Buy" Rating for Alder Biopharmaceuticals (ALDR)
www.americanbankingnews.com - March 30 at 2:09 PM
Alder Biopharmaceuticals Target of Unusually High Options Trading (ALDR)Alder Biopharmaceuticals Target of Unusually High Options Trading (ALDR)
www.americanbankingnews.com - March 30 at 7:14 AM
Zacks: Brokerages Anticipate Alder Biopharmaceuticals Inc (ALDR) Will Post Earnings of -$1.26 Per ShareZacks: Brokerages Anticipate Alder Biopharmaceuticals Inc (ALDR) Will Post Earnings of -$1.26 Per Share
www.americanbankingnews.com - March 30 at 3:20 AM
Alder Biopharmaceuticals (ALDR) PT Raised to $26.00 at BMO Capital MarketsAlder Biopharmaceuticals (ALDR) PT Raised to $26.00 at BMO Capital Markets
www.americanbankingnews.com - March 29 at 11:52 PM
Alder Biopharmaceuticals (ALDR) "Buy" Rating Reiterated at MizuhoAlder Biopharmaceuticals' (ALDR) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - March 28 at 9:32 AM
Alder Biopharmaceuticals (ALDR) Lowered to "Strong Sell" at ValuEngineAlder Biopharmaceuticals (ALDR) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Alder Biopharmaceuticals (ALDR) Rating Lowered to Sell at BidaskClubAlder Biopharmaceuticals (ALDR) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:49 AM
Mid-Day Market Update: Crude Oil Up 2.5%; General Mills Shares Plunge - BenzingaMid-Day Market Update: Crude Oil Up 2.5%; General Mills Shares Plunge - Benzinga
www.benzinga.com - March 22 at 8:28 AM
Alder Biopharmaceuticals Inc. (ALDR) Is Sinking After CEO Steps Down - NasdaqAlder Biopharmaceuticals Inc. (ALDR) Is Sinking After CEO Steps Down - Nasdaq
www.nasdaq.com - March 22 at 8:28 AM
Here’s Why Alder BioPharmaceuticals And Prothena Corporation Are Moving TodayHere’s Why Alder BioPharmaceuticals And Prothena Corporation Are Moving Today
finance.yahoo.com - March 22 at 8:28 AM
Heres Why Alder Biopharmaceuticals Dropped as Much as 18% TodayHere's Why Alder Biopharmaceuticals Dropped as Much as 18% Today
www.msn.com - March 21 at 5:36 PM
Alder Biopharmaceuticals Inc (ALDR) Receives Consensus Recommendation of "Buy" from AnalystsAlder Biopharmaceuticals Inc (ALDR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 21 at 3:56 PM
Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer - GlobeNewswire (press release)Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:57 AM
Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive OfficerAlder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer
finance.yahoo.com - March 20 at 5:16 PM
Alder Biopharmaceuticals Inc (ALDR) Expected to Earn FY2020 Earnings of ($3.32) Per ShareAlder Biopharmaceuticals Inc (ALDR) Expected to Earn FY2020 Earnings of ($3.32) Per Share
www.americanbankingnews.com - March 19 at 9:26 AM
 Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) to Announce -$1.26 EPS Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) to Announce -$1.26 EPS
www.americanbankingnews.com - March 13 at 1:16 AM
Alder Biopharmaceuticals (ALDR) Raised to Hold at BidaskClubAlder Biopharmaceuticals (ALDR) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 11 at 7:10 PM
Leerink Swann Reaffirms Outperform Rating for Alder Biopharmaceuticals (ALDR)Leerink Swann Reaffirms Outperform Rating for Alder Biopharmaceuticals (ALDR)
www.americanbankingnews.com - March 7 at 11:32 AM
Alder Biopharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($1.36) Per Share (ALDR)Alder Biopharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($1.36) Per Share (ALDR)
www.americanbankingnews.com - March 7 at 8:16 AM
Alder Biopharmaceuticals Inc (ALDR) Stake Boosted by Senzar Asset Management LLCAlder Biopharmaceuticals Inc (ALDR) Stake Boosted by Senzar Asset Management LLC
www.americanbankingnews.com - March 5 at 3:44 PM
Alder Biopharmaceuticals (ALDR) Upgraded at Zacks Investment ResearchAlder Biopharmaceuticals (ALDR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 1 at 6:42 PM
Q1 2018 EPS Estimates for Alder Biopharmaceuticals Inc Increased by Analyst (ALDR)Q1 2018 EPS Estimates for Alder Biopharmaceuticals Inc Increased by Analyst (ALDR)
www.americanbankingnews.com - March 1 at 8:36 AM
Carillon Tower Advisers Inc. Invests $14.68 Million in Alder Biopharmaceuticals Inc (ALDR) StockCarillon Tower Advisers Inc. Invests $14.68 Million in Alder Biopharmaceuticals Inc (ALDR) Stock
www.americanbankingnews.com - March 1 at 5:40 AM
Alder Biopharmaceuticals Inc (ALDR) Shares Bought by Ascend Capital LLCAlder Biopharmaceuticals Inc (ALDR) Shares Bought by Ascend Capital LLC
www.americanbankingnews.com - March 1 at 4:40 AM
Alder Biopharmaceuticals (ALDR) Given a $23.00 Price Target by Cowen AnalystsAlder Biopharmaceuticals (ALDR) Given a $23.00 Price Target by Cowen Analysts
www.americanbankingnews.com - February 27 at 7:22 PM
Alder Biopharmaceuticals (ALDR) Q4 2017 Earnings Conference Call TranscriptAlder Biopharmaceuticals (ALDR) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - February 27 at 5:54 PM
Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - GlobeNewswire (press release)Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:20 AM

SEC Filings

Alder BioPharmaceuticals (NASDAQ:ALDR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alder BioPharmaceuticals (NASDAQ:ALDR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alder BioPharmaceuticals (NASDAQ ALDR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.